Allergan Aesthetics has completed the acquistion of Soliton adding to its portfolio of non-invasive body contouring treatments to now include a proven treatment for the appearance of cellulite. The Resonic device received U.S. Food and Drug Administration (FDA) 510(k) clearance for the short-term improvement in the appearance of cellulite, and that clearance has now been expanded to long-term improvement up to one year. In recent clinical data submitted to the FDA, Resonic demonstrated significant improvement in the appearance of cellulite and about 97 percent of participants (n=67) found there was good improvement in the appearance of cellulite at 52-weeks post-treatment. Resonic also received FDA 510(k) clearance for use in conjunction with laser for black ink tattoo removal in Fitzpatrick Skin Type I-III patients. "We welcome the Soliton team to Allergan Aesthetics and the opportunity to offer healthcare providers and their patients a new, non-invasive option to reduce the appearance of cellulite," says Carrie Strom, president of global Allergan Aesthetics and senior vice president of AbbVie. "In a recent survey of aesthetics consumers, cellulite was cited as a top 5 aesthetic concern, and this technology offers a new approach to treatment."
Related Articles
Allergan Aesthetics Celebrated Third Annual Botox Day
Allergan Aesthetics Acquires Soliton and Resonic
Allergan Aesthetics Continues Partnership with Girls Inc.